immunosuppressants/anti-neoplastic agents Flashcards Preview

UWorld > immunosuppressants/anti-neoplastic agents > Flashcards

Flashcards in immunosuppressants/anti-neoplastic agents Deck (32):
1

methotrexate

MOA: folic acid analog, inhibits dihydrofolate reductase
USE: cancer, RA, IBD, psoriasis, abortion
ADR: myelosuppression (leucovorin), teratogen, macrovesicular fatty change in liver

2

5-FU

MOA: pyrimidine analog that binds folic acid, inhibits thymidylate synthase
USE: cancer
ADR: myelosuppression (leucovorin), photosensitivity

3

cytarabine

MOA: pyrimidine analog, inhibits DNA polymerase
USE: leukemia, lymphoma
ADR: panCYTopenia

4

6-MP, azathioprine

MOA: purine analogs, activated by HGPRT
USE: RA, SLE, preventing organ rejection, IBD, leukemia
ADR: myelosuppression

5

dactinomycin

MOA: intercalates in DNA
USE: childhood tumors
ADR: myelosuppression

6

doxorubicin

MOA: generates free radicals, intercalates in DNA and breaks it
USE: cancer
ADR: dilated cardiomyopathy (use dexrazoxane to prevent), myelosuppression

7

bleomycin

MOA: free radicals break DNA strains
USE: cancer
ADR: pulmonary fibrosis, skin changes

8

cyclophosphamide

MOA: alkylating agent
USE: cancer
ADR: myelosuppression, hemorrhagic cystitis (mesna)

9

busulfan

MOA: cross-links DNA
USE: CML, bone marrow ablation before transplantation
ADR: severe myelosuppression, pulmonary fibrosis

10

cisplatin, carboplatin

MOA: cross-links DNA
USE: cancer
ADR: nephrotoxicity, acoustic nerve damage (prevent with amifostine and chloride diuresis)

11

etoposide, teniposide

MOA: inhibits TOPOisomerase II
USE: cancer
ADR: myelosuppression, alopeica

12

tamoxifen, raloxifene

MOA: SERM antagonist in breast, agonist in bone
USE: breast cancer, osteoporosis
ADR: hot flashes, risk of endometrial cancer (only tamoxifen)

13

trastuzumab

herceptin
MOA: HER-2 antibody
USE: HER-2 breast cancer, gastric cancer
ADR: cardiotoxicity, "HEARTceptin"

14

rituximab

MOA: CD20 antibody
USE: cancer, RA, ITP
ADR: risk of PML

15

vemurafenib

MOA: inhibits BRaf kinase
USE: metastatic melanoma

16

bevacizumab

MOA: VEGF antibody
USE: cancer
ADR: hemorrhage, impaired would healing

17

cyclosporine

MOA: calcineurin inhibitor, binds cyclophilin, prevents IL-2, blocks T-cell activation
USE: transplant rejection prophylaxis, psoriasis, RA
ADR: nephrotoxicity, gingival hyperplasia, hirsutism, others

18

tacrolimus

MOA: calcineurin inhibitor, binds FKBP
USE: transplant rejection prophylaxis
ADR: nephrotoxicity, risk of DM

19

rapamycin

sirolimus
MOA: mTOR inhibitor, binds FKBP, blocks IL-2....
MOA: kidney transplant rejection prophylaxis
ADR: non-nephrotoxic

20

basiliximab

MOA: IL-2 antibody
USE: kidney transplant rejection prophylaxis
ADR: edema, HTN, tremor

21

azathioprine

MOA: precursor of 6-MP, inhibits lymphocyte proliferation by blocking nucleotide synthesis
USE: transplant rejection, RA, Crohn, other autoimmune

22

glucocorticoids

MOA: inhibit NF-kB to suppress B and T cell function by decreasing transcription of cytokines

23

use of IFN-alpha

HBV, HCV, kaposi, hairy cell leukemia, condyloma acuminatum, renal cell carcinoma, malignant melanoma

24

use of IFN-beta

MS

25

use of IFN-gamma

CGD

26

alemtuzumab

MOA: CD52
USE: CLL

27

cetuximab

MOA: EGFR

28

infliximab, adalimumab

MOA: TNF-alpha antibody
USE: PAIR (HLA-B27)

29

natalizumab

MOA: alpha4-integrin
USE: MS, Crohn

30

abciximab

MOA: glycoprotein IIb/IIIa antibody
USE: anti-platelet to prevent ischemic complications in percutaneous coronary intervention

31

denosumab

MOA: RANKL (inhibits osteoclast maturation)
USE: osteoporosis

32

palivizumab

MOA: RSV F protein
USE: RSV prophylaxis for high-risk infants